Complete – Medication Tracker

Complete - Medication Tracker

myAbbVieCare

AD Move

PSS: Early ID

IBD Disk

Programa de Soporte a Paciente

AbbVie Events App

IBD Disk Czech Republic

AbbVie Supply Chain Mobile App

Domain Not Resolving

SSL by Default

DNSSEC

Google Maps

Font Awesome

LetsEncrypt

nginx

Organization Schema

reCAPTCHA

Cloudflare CDN

SVP and President, Operations

Azita Gerhardt

SVP, AbbVie, and President, Global Allergan Aesthetics

Carrie Strom

SVP, AbbVie and President, U.S. Commercial Operations

Elaine Sorg

Associate Director, Process Improvement | Global Business Process Owner (BPO)

Hayk Grigoryan

EVP, Chief Strategy Officer

Henry Gosebruch

CFO Latin America Allergan Aesthetics Business – VP of Finance

Juan Duque

Vice Chairman, External Affairs and Chief Legal Officer

Laura Schumacher

VP, Information Technology & CIO

Mark Stahl

Vice Chairman and President

Michael Severino

Engineering

Mike Carlin

Jonathon Kellerman

Roxanne Austin

Roy S. Roberts

Assil Omar

William H.L. Burnside

Glenn Tilton

Edward Liddy

Frederick Waddell

Tariq Ghayur

Distinguished Research Fellow

Axel Arosenius

Psychiatry Specialty Representative

Ric A. Gonzalez

Chairman of the Board & Chief Executive Officer

Nicholas Donoghue

Executive Vice President, Chief Business and Strategy Officer

Vijay Raghavan

Associate Vice President, Marketing Analytics & Business Insights

Sanjay Nilapwar

Principal Scientist

Roopal Thakkar

Executive Vice President, Research & Development and Chief Scientific Officer

James Holdsworth

Architect, Technology II

Carisma Therapeutics is a biotech company that develops novel chimeric antigen receptor macrophage technology to treat solid tumors.

Exicure is developing a new class of immunomodulatory and gene silencing drugs against validated targets.

Jnana Therapeutics develops innovative therapies using a chemoproteomics drug discovery platform.

Effector Therapeutics is an early-stage company focused on the discovery and development of small molecule cancer therapeutics.

Caribou Biosciences is a biotechnology company that develops CRISPR technologies and allogenic cell therapies for oncology.

Alector is combining state-of-the-art antibody technology and recent discoveries in neuroimmunology and human genetics to develop novel.

Rheostat Therapeutics is a bio therapeutics company.

Inventiva is a biopharmaceutical company with several drug candidates at clinical and preclinical stage.

Disarm Therapeutics is a biotechnology company developing disease-modifying therapeutics for patients with axonal degeneration.

Lodo Therapeutics is a drug discovery and development company.

Venture Capital Investors with Investments in Greater Seattle Area

Female Founded Corporate VC Investors with Investments in Silicon Valley

Investors Active in Switzerland

Female Founded Investors active in Virginia

AbbVie is a biopharmaceutical company that develops pharmaceuticals and medical devices. The company provides products and services to therapeutic areas including immunology, oncology, neuroscience, eye care, virology, women's health, and gastroenterology advancing treatments across various therapeutic areas.

Post-IPO Debt - AbbVie

Post-IPO Equity - AbbVie

North Chicago

Illinois

United States

North America

AbbVie

The Stock Market Is Soaring but These 2 Stocks Are Still Dirt Cheap Buys

Endocrinology Drugs Market Analysis by Therapy Area, Distribution Channel and Region - A Forecasted $53.85 Billion Industry by 2030

Specialty Pharmaceuticals Research Report: Increased Reimbursement Through Medical and Pharmacy Benefits Driving the Market, Reaching $965 Billion by 2030

Roche: CE marking in ovarian cancer

Nov 18, 2024

AbbVie Gets European OK of Elahere in Platinum-Resistant Ovarian Cancer

More news from Dow Jones Newswires

AbbVie bags EU nod for key drug from ImmunoGen takeover

A medication used to treat various autoimmune conditions by reducing inflammation.

Precision medicine at AbbVie involves using advanced technologies and data science to tailor treatments to individual patients, focusing on areas like cancer, immunology, neuroscience, and eye care.

AbbVie conducts extensive genomics research to understand disease biology and develop personalized medicines, utilizing genomic insights from diverse sources to enhance drug discovery and development.

A treatment for certain types of cancer, including chronic lymphocytic leukemia and mantle cell lymphoma.

ARCH is a tool that integrates various data sets to provide insights into diseases, discover new treatment indications, and understand molecular aspects of conditions.

A medication used to treat rheumatoid arthritis and other inflammatory conditions.

Germany

Europe

India

Asia

United Kingdom

Ireland

HTML5

Symantec Email Security.Cloud

Akamai Intelligent Platform

Google Drive

Bootstrap

Google Analytics

Wordpress

Apache Server

Amazon Route 53

AbbVie owns BioDisplay Technologies

AbbVie owns AbbVie

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

news impact assignment basic	general	Mar 8, 2024 1:55 PM	3f4f631b
public peers	general
news daily refresh	general	Dec 4, 2024 2:16 PM	62e3a364
news processing daily refresh	general	Sep 4, 2024 12:26 PM	8a734fa1
news impact assignment daily	general	Sep 4, 2024 2:13 AM	3badcf65
news processing basic	general	Mar 8, 2024 1:55 PM	8e4dd4d4
company summary	general	Aug 30, 2024 9:32 PM	8ec78bf2
signals	general
crunchbase trigger	general	Nov 25, 2024 9:06 AM	7ad27f12
crunchbase profile	general	Nov 25, 2024 11:39 AM	15213bd3
li profile	general
translate crunchbase fundingrounds	general	Nov 25, 2024 2:15 PM	4c83058a
peers	general
news basic	general	Dec 4, 2024 2:13 PM	8d2287cd
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:ABBVIE

AbbVie Inc.

Last Close

171.73

22/11 21:00

Market Cap

296.91B

Beta: -

Volume Today

11.33M

Avg: -